| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4530722
Max Phase: Preclinical
Molecular Formula: C17H22F3N3O
Molecular Weight: 341.38
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COCCCNc1nn(C2CCCC2)c2ccc(C(F)(F)F)cc12
Standard InChI: InChI=1S/C17H22F3N3O/c1-24-10-4-9-21-16-14-11-12(17(18,19)20)7-8-15(14)23(22-16)13-5-2-3-6-13/h7-8,11,13H,2-6,9-10H2,1H3,(H,21,22)
Standard InChI Key: FYNPGKLLAULPQF-UHFFFAOYSA-N
Associated Targets(non-human)
Phosphodiesterase 5A 420 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 341.38 | Molecular Weight (Monoisotopic): 341.1715 | AlogP: 4.62 | #Rotatable Bonds: 6 |
| Polar Surface Area: 39.08 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 2.67 | CX LogP: 3.73 | CX LogD: 3.73 |
| Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.78 | Np Likeness Score: -1.36 |
References
| 1. Bollenbach M, Lugnier C, Kremer M, Salvat E, Megat S, Bihel F, Bourguignon JJ, Barrot M, Schmitt M.. (2019) Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model., 177 [PMID:31158744] [10.1016/j.ejmech.2019.05.026] |
Source
Source(1):